Related Experiment Video
Updated: Aug 6, 2026
10:42
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
Published on: February 27, 2019
Peptide-functionalized nanoemulsions with exendin-4 as a model ligand
Natasa Holler1, Bernd Gesslbauer2, Carmen Tam-Amersdorfer3
1University of Graz, Institute of Pharmaceutical Sciences, Pharmaceutical Technology & Biopharmacy, Graz, Austria.
International Journal of Pharmaceutics: X
|July 19, 2026
Summary
Exendin-4 functionalized nanoemulsions (ex-4 NE) show enhanced metabolic effects for obesity treatment, primarily by amplifying biological responses, not just receptor uptake. This offers a promising approach for metabolic disorders.
Area of Science:
- Biotechnology and Nanomedicine
- Cell Biology and Metabolism
Background:
- Glucagon-like peptide-1 receptor (GLP-1R) agonists are investigated for obesity and metabolic disorders.
- The impact of surface-presented GLP-1R ligands on nanocarrier biological effects is not well understood.
Purpose of the Study:
- To develop and evaluate exendin-4 functionalized nanoemulsions (ex-4 NE) for cellular uptake and metabolic activity.
- To elucidate the mechanism of enhanced biological response by ex-4 NE compared to free exendin-4.
Main Methods:
- Development of exendin-4 functionalized nanoemulsions (ex-4 NE).
- Assessment of cellular uptake and colocalization with GLP-1R in 3T3-L1 pre-adipocytes and adipocytes.
- Evaluation of metabolic effects, including adipogenesis and lipid accumulation, under varying ex-4 NE concentrations and treatment timings.
Main Results:
- Ex-4 NE exhibited higher cellular uptake than non-targeted nanoemulsions, influenced by cell differentiation stage.
- Ex-4 NE demonstrated significantly enhanced GLP-1R-dependent metabolic effects compared to free exendin-4, even at lower concentrations.
- Enhanced activity was attributed to amplified biological responses and multivalent interactions from high local ligand density, not solely receptor-mediated uptake.
Conclusions:
- Exendin-4 functionalization of nanoemulsions amplifies biological responses, offering a potent strategy for metabolic disorder treatment.
- The enhanced efficacy stems from increased local ligand density and multivalent interactions, improving receptor activation.
- Nanoemulsion uptake mechanisms are complex and not exclusively dependent on direct GLP-1R interaction.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...